HYBRID EVENT: You can participate in person at Singapore or Virtually from your home or work.
2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
AI in Cancer Research and Drug Development
AI in Cancer Research and Drug Development
AI is becoming a cornerstone in cancer research and drug development, streamlining the process of discovering new treatments. Machine learning models can analyze vast amounts of molecular and clinical data, helping researchers identify promising drug candidates and predict their efficacy. By simulating how different compounds interact with cancer cells, AI can expedite the identification of therapeutic targets. This accelerates the drug development pipeline, potentially bringing effective treatments to market more quickly. As AI continues to evolve, its role in uncovering innovative cancer therapies will only increase, shaping the future of cancer research.
Committee Members
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States CIOC 2026 Speakers
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China